Effect of splenectomy based on inverse probability weighting of the propensity score on Wilson's disease with hypersplenism: A retrospective cohort study

Chen,Hong; Wang,Xie; Zhang,Juan; Xie,Daojun

doi:10.3892/etm.2023.11919

Effect of splenectomy based on inverse probability weighting of the propensity score on Wilson's disease with hypersplenism: A retrospective cohort study

Authors:
- Hong Chen
- Xie Wang
- Juan Zhang
- Daojun Xie
View Affiliations

Affiliations: Department of Neurology, The First Affiliated Hospital of Anhui University of Traditional Chinese Medicine, Hefei, Anhui 230031, P.R. China
Published online on: March 29, 2023 https://doi.org/10.3892/etm.2023.11919
Article Number: 220
Copyright: © Chen et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Hypersplenism is a long‑term complication of Wilson's disease (WD). Patients often have to stop copper excretion treatment due to the decrease in blood cell count aggravation of abnormal liver function, anaemia, bleeding caused by coagulation dysfunction. The present study aimed to explore the effect of splenectomy on serum, biochemical indicators and neurological function in patients with hypersplenism of WD to evaluate the impact of splenectomy on their survival and prognosis. Due to the non‑randomness of splenectomy in patients with hypersplenism in WD in the present study, the propensity scoring model and inverse probability treatment weighting were used to evaluate the age, sex, duration of the disease. A total of 86 patients (40 with and 46 without splenectomy) were included in the present study. The baseline and preoperative data were adjusted by the inverse probability weighting method using the propensity score model. There was no significant difference in distribution of propensity scores between the two groups (P>0.05). There were significant differences in time‑weighted PLT levels in patients with hypersplenism of WD [after adjustment, odd ratio (OR)=0.010; 95% CI, 0.0013‑0.047; P<0.001]. The time‑weighted Child‑Pugh scores after adjustment also suggested a significant difference (OR=0.0684; 95% CI, 0.018‑0.207; P<0.001). The time‑weighted modified Young scale scores demonstrated no statistical significance (after adjustment, OR=0.294; 95% CI, 0.074‑1.001; P>0.05). Survival data showed a mean survival time of 11.2±3.15 years with a 10‑year survival rate of 64.97% for patients with non-splenectomy and 12.9±2.62 years with a 10‑year survival rate of 92.11% for patients with splenectomy, which was statistically significant (P<0.05). Due to crossover of survival curves at a later stage, the data were analysed using landmark analysis. The results suggested that splenectomy decreased death rate within 10 years by 84% compared with the non‑splenectomy group (HR=0.158; 95% Cl, 0.0198‑1.2545; P<0.05), but the survival rate of the two groups was not statistically significant after 10 years. (HR=0.445; 95% Cl, 0.2463‑0.8022; P>0.05). In conclusion, splenectomy significantly improved levels of PLT and liver function in patients with hypersplenism of WD, neurological function did not deteriorate and survival rate was improved.

View Figures

View References

1	Compston A: Progressive lenticular degeneration: A familial nervous disease associated with cirrhosis of the liver, by S. A. Kinnier Wilson, (from the national hospital, and the laboratory of the national hospital, queen square, London) brain 1912: 34; 295-509. Brain. 132:1997–2001. 2009.PubMed/NCBI View Article : Google Scholar
2	Strickland GT, Chang NK and Beckner WM: Hypersplenism in Wilson's disease. Gut. 13:220–224. 1972.PubMed/NCBI View Article : Google Scholar
3	Poujois A and Woimant F: Wilson's disease: A 2017 update. Clin Res Hepatol Gastroenterol. 42:512–520. 2018.PubMed/NCBI View Article : Google Scholar
4	Zeng DB, Di L, Zhang RC, Guo QL, Duan BW, Jia CY, Chen F, Lin DD, Zang YJ and Lu SC: The effect of splenectomy on the reversal of cirrhosis: A prospective study. Gastroenterol Res Pract. 2019(5459427)2019.PubMed/NCBI View Article : Google Scholar
5	Rabiner AM, et al: Hepatolenticular degeneration following splenectomy, interrelationship of the reticuloendothlial system and central nervous system. Arch Int Med, 1941.
6	Sternlieb I, Scheinberg IH and Walshe JM: Bleeding oesophageal varices in patients with Wilson's disease. Lancet. 1:638–641. 1970.PubMed/NCBI View Article : Google Scholar
7	Cai YL, Yang XT and Yang RM: Discussion on splenectomy in hepatolenticular degeneration (with 42 cases report). J Clin Neurol. 6:131–133. 1993.(In Chinese).
8	Li LY, Yang WM, Chen HZ, Wu YH, Fang X, Zhang J, Wang Z, Han YS and Wang Y: Successful splenectomy for hypersplenism in Wilson's disease: A single center experience from China. PLoS One. 10(e0124569)2015.PubMed/NCBI View Article : Google Scholar
9	Guo BB, Yu QS, Sheng Y, et al: Platelet changes and its clinical significance in patients with hepatolenticular degeneration complicated with hypersplenism before and after splenectomy. J Liaoning Univ Tradit Chin Med. 21:134–137. 2019.(In Chinese).
10	Yang W, Yu QS and Pan JF: Effect of platelet level on operation and prognosis in patients with hepatolenticular degeneration and hypersplenism undergoing splenectomy. Shaanxi Med J. 49:1403–1407. 2020.(In Chinese).
11	Wei FS, Yu QS, Pan JF, Shen Y, Zhang Q, Wang Z and Hunag L: Effect of splenectomy on liver function in patients with hepatolenticular degeneration and hypersplenism. Guangxi Med. 42:2475–2491. 2020.(In Chinese).
12	Wang XM, Zhang FZ, Yu QS, et al: Plenectomy in the treatment of hepatolenticular degeneration with hypersplenism in children. J Hepatobiliary Pancreat Surg. 19:217–219. 2007.(In Chinese).
13	Qian Y, Pan JF, Huang L, Wang Z, Jing W and Yu Q: Hepatolenticular degeneration with moderate to severe hypersplenism Analysis of related factors of complications after splenectomy. Shandong Med J. 62:63–66. 2022.(In Chinese).
14	Carry PM, Vanderlinden LA, Dong F, Buckner T, Litkowski E, Vigers T, Norris JM and Kechris K: Inverse probability weighting is an effective method to address selection bias during the analysis of high dimensional data. Genet Epidemiol. 45:593–603. 2021.PubMed/NCBI View Article : Google Scholar
15	Yang RM: Hepatolenticular degeneration. 9th Edition. People's Health Publishing House, Beijing, 2015.
16	Rosencrantz R and Schilsky M: Wilson disease: Pathogenesis and clinical considerations in diagnosis and treatment. Semin Liver Dis. 31:245–259. 2011.PubMed/NCBI View Article : Google Scholar
17	Ferenci P, Caca K, Loudianos G, Mieli-Vergani G, Tanner S, Sternlieb I, Schilsky M, Cox D and Berr F: Diagnosis and phenotypic classification of Wilson disease. Liver Int. 23:139–142. 2003.PubMed/NCBI View Article : Google Scholar
18	Hou Y and Sun GX: Diagnostic classification criteria and clinical significance of hypersplenism in portal hypertension. J Mod Integr Tradit Chin West Med. 18(3603)2009.(In Chinese).
19	Pugh RN, Murray-Lyon IM, Dawson JL, Pietroni MC and Williams R: Transection of the oesophagus for bleeding oesophageal varices. Br J Surg. 60:646–649. 1973.PubMed/NCBI View Article : Google Scholar
20	Zhou XX, Qin HL, He RX, Chen DB, Wu C, Feng L, Li XH and Liang XL: Clinical characteristics of patients with delayed hepatolenticular degeneration. Zhonghua Nei Ke Za Zhi. 58:501–507. 2019.PubMed/NCBI View Article : Google Scholar : (In Chinese).
21	Mansournia MA and Altman DG: Inverse probability weighting. BMJ. 352(i189)2016.PubMed/NCBI View Article : Google Scholar
22	Rubin DB: Estimating causal effects from large data sets using propensity scores. Ann Intern Med. 127:757–763. 1997.PubMed/NCBI View Article : Google Scholar
23	Liu L, Nevo D, Nishihara R, Cao Y, Song M, Twombly TS, Chan AT, Giovannucci EL, VanderWeele TJ, Wang M and Ogino S: Utility of inverse probability weighting in molecular pathological epidemiology. Eur J Epidemiol. 33:381–392. 2018.PubMed/NCBI View Article : Google Scholar
24	Yoshizumi T, Itoh S, Shimokawa M, Inokuchi S, Harada N, Takeishi K, Mano Y, Yoshiya S, Kurihara T, Nagao Y, et al: Simultaneous splenectomy improves outcomes after adult living donor liver transplantation. J Hepatol. 74:372–379. 2021.PubMed/NCBI View Article : Google Scholar
25	Brauer DL, Rapoport AP, Yanovich S and Akpek G: Splenectomy as a measure to treat prolonged post-transplant cytopenia associated with hypersplenism. Bone Marrow Transplant. 49:717–719. 2014.PubMed/NCBI View Article : Google Scholar
26	Inagaki Y, Sugimoto K, Shiraki K, Tameda M, Kusagawa S, Nojiri K, Ogura S, Yamamoto N, Takei Y, Ito M, et al: The long-term effects of splenectomy and subsequent interferon therapy in patients with HCV-related liver cirrhosis. Mol Med Rep. 9:487–492. 2014.PubMed/NCBI View Article : Google Scholar
27	McKenzie CV, Colonne CK, Yeo JH and Fraser ST: Splenomegaly: Pathophysiological bases and therapeutic options. Int J Biochem Cell Biol. 94:40–43. 2018.PubMed/NCBI View Article : Google Scholar
28	Schwabl P, Seeland BA, Riedl F, Schubert TL, Königshofer P, Brusilovskaya K, Petrenko O, Hofer B, Schiefer AI, Trauner M, et al: Splenectomy ameliorates portal pressure and anemia in animal models of cirrhotic and non-cirrhotic portal hypertension. Adv Med Sci. 67:154–162. 2022.PubMed/NCBI View Article : Google Scholar
29	Yamamoto N, Okano K, Oshima M, Akamoto S, Fujiwara M, Tani J, Miyoshi H, Yoneyama H, Masaki T and Suzuki Y: Laparoscopic splenectomy for patients with liver cirrhosis: Improvement of liver function in patients with Child-Pugh class B. Surgery. 158:1538–1544. 2015.PubMed/NCBI View Article : Google Scholar
30	Shi XB, Feng JK, Wang JH and Jiang XQ: Does splenectomy significantly improve the prognosis of hepatocellular carcinoma patients with hypersplenism? A systematic review and meta-analysis. Ann Transl Med. 9(641)2021.PubMed/NCBI View Article : Google Scholar
31	Wang MJ, Ling WW, Wang H, Meng LW, Cai H and Peng B: Non-invasive evaluation of liver stiffness after splenectomy in rabbits with CCl₄-induced liver fibrosis. World J Gastroenterol. 22:10166–10179. 2016.PubMed/NCBI View Article : Google Scholar
32	Wang Y, Guo X, Jiao G, Luo L, Zhou L, Zhang J and Wang B: Splenectomy promotes macrophage polarization in a mouse model of concanavalin A-(ConA-) Induced liver fibrosis. Biomed Res Int. 2019(5756189)2019.PubMed/NCBI View Article : Google Scholar
33	Elchaninov AV, Fatkhudinov TK, Vishnyakova PA, Nikitina MP, Lokhonina AV, Makarov AV, Arutyunyan IV, Kananykhina EY, Poltavets AS, Butov KR, et al: Molecular mechanisms of splenectomy-induced hepatocyte proliferation. PLoS One. 15(e0233767)2020.PubMed/NCBI View Article : Google Scholar
34	Liang QS, Xie JG, Yu C, Feng Z, Ma J, Zhang Y, Wang D, Lu J, Zhuang R and Yin J: Splenectomy improves liver fibrosis via tumor necrosis factor superfamily 14 (LIGHT) through the JNK/TGF-β1 signaling pathway. Exp Mol Med. 53:393–406. 2021.PubMed/NCBI View Article : Google Scholar
35	Zheng Z, Wang H, Li L, Zhang S, Zhang C, Zhang H, Ji F, Liu X, Zhu K, Kong G and Li Z: Splenectomy enhances the Ly6C^low phenotype in hepatic macrophages by activating the ERK1/2 pathway during liver fibrosis. Int Immunopharmacol. 86(106762)2020.PubMed/NCBI View Article : Google Scholar
36	Zeng DB, Di L, Guo QL, Ding J, Zhao XF and Lu SC: Splenectomy with portoazygous disconnection for correction of systemic hemodynamic disorders in hepatic cirrhosis patients with portal hypertension: A prospective single-center cohort study. Can J Gastroenterol Hepatol. 2020(8893119)2020.PubMed/NCBI View Article : Google Scholar
37	Weledji EP: Benefits and risks of splenectomy. Int J Surg. 12:113–119. 2014.PubMed/NCBI View Article : Google Scholar
38	Członkowska A, Litwin T, Dusek P, Ferenci P, Lutsenko S, Medici V, Rybakowski JK, Weiss KH and Schilsky ML: Wilson disease. Nat Rev Dis Primers. 4(21)2018.PubMed/NCBI View Article : Google Scholar
39	Grasedyck K: D-penicillamine-side effects, pathogenesis and decreasing the risks. Z Rheumatol. 47 (Suppl 1):S17–S19. 1988.PubMed/NCBI(In German).
40	Langan MN and Thomas P: Penicillamine-induced liver disease. Am J Gastroenterol. 82:1318–1319. 1987.PubMed/NCBI